Debjit Chattopadhyay
Stock Analyst at Guggenheim
(3.53)
# 889
Out of 4,914 analysts
92
Total ratings
54.22%
Success rate
4.13%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debjit Chattopadhyay
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical | Reiterates: Buy | $64 | $27.14 | +135.81% | 3 | Jun 20, 2025 | |
| DYN Dyne Therapeutics | Reiterates: Buy | $50 | $9.91 | +404.54% | 5 | Jun 18, 2025 | |
| QURE uniQure | Reiterates: Buy | $28 | $14.45 | +93.77% | 6 | May 12, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $55 → $45 | $12.33 | +264.96% | 2 | May 12, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Buy | $81 → $97 | $84.91 | +14.24% | 3 | May 8, 2025 | |
| KRYS Krystal Biotech | Maintains: Buy | $195 → $189 | $153.03 | +23.51% | 4 | May 7, 2025 | |
| BEAM Beam Therapeutics | Maintains: Buy | $78 → $55 | $20.15 | +172.95% | 3 | May 7, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $112 → $98 | $16.75 | +485.07% | 5 | May 7, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $65 → $64 | $43.37 | +47.57% | 5 | May 1, 2025 | |
| MAZE Maze Therapeutics | Reiterates: Buy | $19 | $15.56 | +22.11% | 2 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $16.57 | +68.98% | 6 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $6.00 | - | 2 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $3.92 | +359.18% | 3 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $17 | $11.14 | +52.60% | 2 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $6.13 | +144.90% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $450 → $558 | $469.16 | +18.94% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $57.68 | - | 1 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $4.75 | +300.00% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $3.46 | +535.84% | 1 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $22.42 | +33.84% | 1 | Jan 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $110 | $58.79 | +87.11% | 3 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $29 | $1.29 | +2,148.06% | 1 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $220 | $6.15 | +3,477.24% | 2 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $339.80 | - | 1 | Jun 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $2.74 | +923.77% | 1 | Dec 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $20 | $8.16 | +145.10% | 2 | Dec 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $270 → $123 | $33.29 | +269.48% | 8 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $54 | $12.94 | +317.31% | 3 | Jul 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $60 | $1.17 | +5,028.21% | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $37.54 | - | 3 | Jun 26, 2017 |
Ultragenyx Pharmaceutical
Jun 20, 2025
Reiterates: Buy
Price Target: $64
Current: $27.14
Upside: +135.81%
Dyne Therapeutics
Jun 18, 2025
Reiterates: Buy
Price Target: $50
Current: $9.91
Upside: +404.54%
uniQure
May 12, 2025
Reiterates: Buy
Price Target: $28
Current: $14.45
Upside: +93.77%
Intellia Therapeutics
May 12, 2025
Maintains: Buy
Price Target: $55 → $45
Current: $12.33
Upside: +264.96%
Soleno Therapeutics
May 8, 2025
Maintains: Buy
Price Target: $81 → $97
Current: $84.91
Upside: +14.24%
Krystal Biotech
May 7, 2025
Maintains: Buy
Price Target: $195 → $189
Current: $153.03
Upside: +23.51%
Beam Therapeutics
May 7, 2025
Maintains: Buy
Price Target: $78 → $55
Current: $20.15
Upside: +172.95%
Sarepta Therapeutics
May 7, 2025
Maintains: Buy
Price Target: $112 → $98
Current: $16.75
Upside: +485.07%
Ionis Pharmaceuticals
May 1, 2025
Maintains: Buy
Price Target: $65 → $64
Current: $43.37
Upside: +47.57%
Maze Therapeutics
Apr 2, 2025
Reiterates: Buy
Price Target: $19
Current: $15.56
Upside: +22.11%
Mar 26, 2025
Reiterates: Buy
Price Target: $28
Current: $16.57
Upside: +68.98%
Feb 10, 2025
Reiterates: Buy
Price Target: n/a
Current: $6.00
Upside: -
Dec 3, 2024
Reiterates: Buy
Price Target: $18
Current: $3.92
Upside: +359.18%
Dec 3, 2024
Reiterates: Buy
Price Target: $17
Current: $11.14
Upside: +52.60%
Nov 7, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $6.13
Upside: +144.90%
Aug 2, 2024
Maintains: Buy
Price Target: $450 → $558
Current: $469.16
Upside: +18.94%
Jun 28, 2024
Assumes: Neutral
Price Target: n/a
Current: $57.68
Upside: -
Apr 30, 2024
Initiates: Buy
Price Target: $19
Current: $4.75
Upside: +300.00%
Mar 26, 2024
Initiates: Buy
Price Target: $22
Current: $3.46
Upside: +535.84%
Jan 18, 2024
Initiates: Buy
Price Target: $30
Current: $22.42
Upside: +33.84%
Sep 13, 2023
Reiterates: Buy
Price Target: $110
Current: $58.79
Upside: +87.11%
Nov 21, 2022
Maintains: Buy
Price Target: $43 → $29
Current: $1.29
Upside: +2,148.06%
Nov 11, 2022
Maintains: Buy
Price Target: $260 → $220
Current: $6.15
Upside: +3,477.24%
Jun 27, 2022
Downgrades: Neutral
Price Target: n/a
Current: $339.80
Upside: -
Dec 16, 2021
Initiates: Buy
Price Target: $28
Current: $2.74
Upside: +923.77%
Dec 15, 2020
Assumes: Buy
Price Target: $20
Current: $8.16
Upside: +145.10%
Aug 24, 2020
Downgrades: Neutral
Price Target: $270 → $123
Current: $33.29
Upside: +269.48%
Jul 9, 2020
Maintains: Buy
Price Target: $60 → $54
Current: $12.94
Upside: +317.31%
Dec 3, 2019
Downgrades: Neutral
Price Target: $60
Current: $1.17
Upside: +5,028.21%
Jun 26, 2017
Downgrades: Neutral
Price Target: n/a
Current: $37.54
Upside: -